Bandung, West Java (ANTARA) - President Joko Widodo (Jokowi) launched a domestically made COVID-19 vaccine called IndoVac that was produced by state-owned pharmaceutical company PT Bio Farma on Thursday.
"This morning, I launch the IndoVac vaccine produced by PT Bio Farma," Jokowi stated at PT Bio Farma's Head Office, here, on Thursday.
Jokowi ensured that the vaccine is domestically produced from upstream to downstream. According to the head of state, the vaccine is the result of hard work of young Indonesian human resources.
"The vaccine production and development takes time, approximately 1.5 years, from the beginning until the launch. They work in silent (manner), and finally, they can release the vaccine now," Jokowi stated.
Related news: IndoVac vaccine is first COVID-19 vaccine produced in Indonesia: BPOM
The head of state remarked that at this time, Bio Farma can produce 20 million doses of the IndoVac vaccine. As for 2023, some 40 million doses of the IndoVac vaccine could be produced.
To this end, President Jokowi urged State-owned Enterprises (SOEs) Minister Erick Thohir and Health Minister Budi Gunadi Sadikin also present at the launch site to continue to encourage Bio Farma to produce vaccines.
Hence, he expressed optimism that Bio Farma would be able to generate major revenues and that Indonesia would harbor an independent spirit in meeting the domestic vaccine needs.
"For the polio vaccine alone, Bio Farma controls 70 percent of the world's market share, 70 percent supplies of the polio vaccine to all countries. This is extraordinary," he emphasized.
Related news: Bio Farma to produce 20 mln IndoVac doses after EUA clearance
In addition to the launch of the IndoVac vaccine, President Jokowi reviewed the vaccine administration process for several residents. As for the Bio Farma Office, some 15 people will receive the vaccine for the first time.
On October 6, President Director of Bio Farma, Honesti Basyir, stated that the IndoVac vaccine had officially received a halal certificate from the Halal Product Assurance Organizing Agency (BPJPH).
Earlier, the vaccine had also received a Good Manufacturing Practice (CPOB) certificate from the National Agency of Drug and Food Control (BPOM), an emergency use permit (EUA) from BPOM, and the Emergency Use Listing (EUL) from the World Health Organization (WHO).
Related news: Bio Farma's IndoVac vaccine obtains BPJPH's halal certificate
Related news: Bio Farma, British firm to develop recombinant factor VIII product
